However, the unbiased identification of variants by either SNP arrays or traditional Sanger sequencing typically requires an allele fraction 425% of the involved specimen. Because the progression from AA to MDS may occur over years or even decades, subclones that ultimately evolve into MDS could be present at very low fractions at the time of AA diagnosis.
Sanger sequencing of specimens from patients with AA has not identified recurrent alterations, suggesting that they are either not present or exist within subclones below the level of detection with this method. Next-generation sequencing to a high-depth of coverage offers the potential to identify subclonal mutations with sensitivity proportional to the depth of sequencing. We developed a platform for exon capture followed by deep sequencing 4 of 219 genes (Supplementary Table 1 ) that are recurrently mutated in hematologic malignancies (see Supplementary Methods). Patients with AA and available blood or bone marrow were identified by searching databases of stored specimens at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. All studies were performed under the approval of the Institutional Review Board of the Dana-Farber Cancer Institute/Harvard Cancer Center.
We identified 39 patients with AA and banked bone marrow or peripheral blood specimens (Table 1) . None of the patients had abnormalities detected by metaphase karyotyping or fluorescence in situ hybridization of bone marrow specimens. Severe AA was defined as a hypocellular bone marrow for age and at least two of the following in the peripheral blood: platelet count o20 000/ mm 3 , a corrected reticulocyte count o1%, and/or absolute neutrophil count (ANC) o500/mm 3 . Patients with peripheral blood ANC o200/mm 3 were categorized as very severe AA. Four patients had a paroxysmal nocturnal hemoglobinuria (PNH) clone identified at 45% based on loss of CD55/CD59 expression by flow cytometry, although none had clinical manifestations of PNH. Six additional patients had pre-existing hematologic disorders (Table 1) .
Paired-end sequencing was performed to mean depth 4450 haploid coverage. Among the 39 patients, we identified nine that each harbored a single non-dbSNP coding variant (Figure 1a) . Seven of the mutations were present in allele fractions less than 10%. All nine mutations were confirmed to be present by Sanger sequencing (if present in X20% of called reads) (Supplementary  Table 2 ) or by mass spectrometry-based genotyping (if present in o20% of called reads) and seven were confirmed to be somatic by Sanger sequencing of either germline material or CD3-positive T-cells. For the remaining two mutations (BCR g.2365393C4T and ASXL1 g.31023451delCATT), neither germline material nor CD3-positive T-cells were available, but both mutations were present in o10% of reads, strongly suggesting that they were somatically acquired. In univariate analysis (Table 1) , harboring a mutation was not associated with any particular demographic factor or clinical factor, although 7 (36.8%) of 19 patients who received IST before sample acquisition had mutations detected, compared with only 2 (10%) of 20 patients who were previously untreated (P ¼ 0.06 by two-sided Fisher's exact test).
We also sequenced four additional patients with bone marrow disorders who did not meet criteria for AA. There were no mutations recovered from a patient with pure red cell aplasia, a patient with transient idiopathic cytopenias or a patient with Diamond-Blackfan anemia. A patient who was initially diagnosed with AA but was found to have monosomy of chromosome 7 in 10% of interphase cells by FISH harbored a DNMT3A V372F mutation in 3.5% of reads (Supplementary Figure 1) .
Among the patients with AA, one harbored a DNMT3A R635W mutation previously described in AML ( Figure 1 , Supplementary Figure 2 ) and two cases harbored premature truncation mutations in ASXL1 (Supplementary Figure 3) . All of these mutations were present in o10% of reads, which was confirmed by mass spectrometry-based genotyping (Supplementary Figures 2, 3 ). To our knowledge, this demonstrates for the first time that sequencing to significant depth can distinguish patients with AA who harbor subclonal mutations associated with MDS and AML. 5 We sorted CD3-positive and CD3-negative populations to determine whether mutations we recovered from unselected cells are present in one or both compartments. Both IKZF3 g.37922201G4A and ASXL1 g.31023451delCATT were only recovered from CD3-negative populations (Figure 1c ). In contrast, BCR g.2365393C4T and CELSR2 g.109805550T4C were present in both CD3-positive and CD3-negative populations at similar frequencies ( Figure 1d, Supplementary Figure 4) . Thus, some but not all subclonal mutations recovered from patients with AA are present within CD3-positive T-cells.
The ASXL1 g.31023451delCATT mutation in patient AA37 was present in 9.3% of reads from a bone marrow specimen obtained 9 months after the initial diagnosis of AA. To determine whether the mutation was present at an earlier timepoint or other mutations arose and then were lost, we sequenced another bone marrow specimen obtained at the time of diagnosis (that is, 9 months prior) using the same platform. No mutations were identified in this earlier specimen with the standard calling algorithm. However, visual inspection of the reads at ASXL1 identified the g.31023451delCATT in 1 of 624 reads (0.16%) (Supplementary Figure 5) , suggesting that the mutant allele expanded B50-fold over 9 months of observation.
In one patient, we identified an M1I mutation in the start codon of b2-microglobulin (B2M), the invariant subunit of the major histocompatibility complex (MHC) class I. Two years after this patient was diagnosed with AA, the patient had a complete and sustained response after treatment with antithymocyte globulin and cyclosporine. The patient relapsed 4 years later, underwent allogeneic HSCT 3 years after that, and was in complete remission 1 year later. The sequenced specimen was obtained after relapse and before HSCT.
Peptides presented by MHC class I are recognized by CD8 þ cytotoxic T-cells, leading to target cell destruction. B2M is required for MHC class I surface expression and CD8 þ T cell function. Letters to the Editor is deleted or mutated in 29% of diffuse large B-cell lymphomas (DLBCL) and the most common mutation (5 of 25 cases with mutations) was at the start codon, 7 exactly as observed in our patient with AA (Figure 1e ). Immunohistochemistry for b2-microglobulin expression in bone marrow obtained from the sequenced specimen demonstrated loss of B2M expression within hematopoietic cells, with preserved staining in surrounding nonhematopoietic cells (Figure 1e ). In comparison, a bone marrow specimen isolated 4 months after allogeneic HSCT demonstrated nearly universal membrane staining within hematopoietic and stromal cells (Figure 1e) .
If the B2M mutation results in complete loss of MHC class I, the cells should become susceptible to natural killer (NK) cellmediated cytotoxicity. Of note, DLBCLs also frequently harbor loss-of-function mutations in CD58, which results in evasion from NK cell cytolysis.
7 CD58 was included in our sequencing panel (Supplementary Table 1 ), but no mutations were recovered in CD58 in any cases. Therefore the B2M-mutated clone may have additional mechanisms of NK cell escape not evident by our targeted sequencing approach.
These results demonstrate that a subset of patients with AA harbor relatively rare clones that contain pathogenic mutations, including premature stop and frame-shift mutations in ASXL1 and a previously described variant in DNMT3A. The paucicellular nature of bone marrow specimens from patients with AA (for example, Figure 1e ) suggests that a significant fraction of the cells sequenced in these specimens may be non-hematopoietic, and thus lack the mutation. As such, the true fraction of hematopoietic cells harboring the mutation may be significantly higher than suggested by the allele burden. Most importantly, nearly all of the Whole-genome sequencing of hematopoietic stem cells from normal individuals has identified a high burden of age-associated mutations. 8 In addition, alterations associated with hematologic malignancies (for example, BCL2-IGH 9, 10 ) can be recovered from a large fraction of the general population. Together, these findings reinforce the point that the presence of mutations within specimens from patients with AA does not prove that those mutations are pathogenic. Further studies are needed to determine whether the recovery of subclonal mutations predicts for either the response to immunosuppressive therapy or malignant evolution, and thus would serve as a valuable assay to guide therapy.
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Age at diagnosis is an important determinant of outcome among patients with multiple myeloma (MM). The median age at diagnosis is 70 years in the United States, which is similar to that in the United Kingdom (73 years) and Sweden (70 years). [1] [2] [3] The subgroup over the age of 75 years represents a population in which the natural history of the disease and outcomes are not well studied. [4] [5] [6] [7] In one report, the median survival was less than 6 
